VistaGen Therapeutics GAAP EPS of -$0.45 beats by $0.04, revenue of $0.30M beats by $0.16M
Source: SeekingAlpha
2026-02-12 16:36:42 ET
More on VistaGen Therapeutics
- Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026
- VistaGen Therapeutics Q3 2026 Earnings Preview
- Biggest stock movers Thursday: DJT, MU, LULU and more
- Seeking Alpha’s Quant Rating on VistaGen Therapeutics
- Historical earnings data for VistaGen Therapeutics
Read the full article on Seeking Alpha
For further details see:
VistaGen Therapeutics GAAP EPS of -$0.45 beats by $0.04, revenue of $0.30M beats by $0.16M
VistaGen Therapeutics Inc.
NASDAQ: VTGN
VTGN Trading
3.92% G/L:
$0.6514 Last:
341,585 Volume:
$0.6302 Open:
VTGN Latest News
March 04, 2026 09:00:00 am
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights - VTGN
February 25, 2026 09:00:00 am
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Lawsuit - VTGN
February 25, 2026 08:30:00 am
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
VTGN Stock Data
$23,061,394
27,595,472
0.51%
65
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
